News

Today’s approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012

Developing improved biologically active molecules has benefited from the use of substituents that are chemically stable, resistant to metabolism, and combine lipophilicity with polarity to improve binding and

The interim analysis demonstrated that treatment with ofatumumab (Arzerra) met the primary endpoint of improving progression free survival (PFS). The study evaluated ofatumumab maintenance therapy versus no further

According to the company, Iluvien (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant, which has a therapeutic effect of up to 36 months. The

The patent covers Full COLD-PCR, a foundation for the company’s highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and

Under the deal, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix is a biologically-derived matrix for in-growing cells, and

Dalbavancin will be commercialized in Italy, Spain, Poland, Portugal, many Eastern European countries, Russia, Turkey and Commonwealth of Independent States. As part of the deal, Durata will receive

The company has entered into an agreement with Sandoz Canada, pursuant to which the latter will produce, use, sell, market and distribute Olanzapine injection in Canada. InnoPharma president

The clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech’s PD-L1 immune checkpoint